A Multi-dose Phase II Trial of Rosuvastatin to Lower Circulating Tissue Factor Bearing Microparticles in Metastatic Breast Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 18 Oct 2017
At a glance
- Drugs Rosuvastatin (Primary)
- Indications Adenocarcinoma; Advanced breast cancer
- Focus Biomarker; Pharmacodynamics
- 12 Oct 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
- 10 Jun 2017 Biomarkers information updated
- 20 Jan 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Dec 2016 as reported by ClinicalTrials.gov record.